Investing Ideas
/
Swedish Pharmaceuticals & Biotech Undervalued based on future growth

Swedish Pharmaceuticals & Biotech Undervalued based on future growth

Name: Financial Insights Based on S&P Global Market Intelligence
Creator: Simply Wall St Pty Ltd
License: https://www.spglobal.com/content/dam/spglobal/corporate/en/documents/secure/MI-FastTrack-Terms-and-Conditions-July-2023.pdf

Results

1 new

Companies which can be considered undervalued when accounting for expected future growth (PEG under 0.8)

1 companies

Vitrolife

Market Cap: SEK 18.0b

Provides assisted reproduction products in Europe, the Middle East, Africa, Asia-Pacific, and the Americas.

New

VITR

SEK 133.10

2.0%

-36.0%